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ORIGINAL ARTICLE
Background/Aims: In patients with heart failure (HF), N-terminal prohormone brain natriuretic peptide (NT-
ProBNP) is a standard prognostic indicator. In addition, uric acid (UA) was recently established as a prognostic
marker for poor outcome in chronic HF. The aim of this study was to determine the combined role of UA and NT-
ProBNP as prognostic markers for short-term outcomes of acute heart failure (AHF). 
Methods: The levels of UA and NT-ProBNP were determined in 193 patients (age, 69 ± 13 years; 76 males) admitted
with AHF. Patients were followed for 3 months and evaluated for cardiovascular events, defined as cardiac death
and/or readmission for HF.  
Results: Of the 193 patients, 23 (11.9%) died and 20 (10.4%) were readmitted for HF during the 3-month follow-
up period. Based on univariate analysis, possible predictors of short-term cardiovascular events were high levels
of UA and NT-ProBNP, low creatinine clearance, no angiotensin converting enzyme inhibitors or angiotensin
receptor blockers, and old age. Multivariate Cox hazard analysis showed that UA levels were independently
associated with increased incidence of cardiovascular events (hazard ratio, 1.115; 95% confidence interval,
1.006 to 1.235; p = 0.037). Kaplan-Meier survival analysis revealed that patients with UA levels > 8.0 mg/dL and
NT-ProBNP levels > 4,210 pg/mL were at highest risk for cardiac events (p = 0.01).  
Conclusions: The combination of UA and NT-ProBNP levels appears to be more useful than either marker
alone as an independent predictor for short-term outcomes in patients with AHF. (Korean J Intern Med 2010;
25:253-259)
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INTRODUCTION
Heart failure (HF) is the one of the most common cardio-
vascular disorders and is associated with high morbidity
and mortality. Although numerous parameters indicate
the prognosis of heart failure, most are costly to evaluate
and are assessed only in research. There is a need for
prognostic parameters that can be measured simply and
inexpensively in any setting. 
Previous studies have demonstrated that N-terminal
prohormone brain natriuretic peptide (NT-ProBNP) levels
have diagnostic and prognostic value in patients with HF.
The NT-ProBNP level was a useful marker in the diagnosis
of HF for complaints of acute dyspnea [1,2]. Other studies
have suggested that in patients with HF, the NT-ProBNP
level is an important predictor for clinical outcomes such
as hospital readmission and mortality [3,4].
Numerous parameters predict the prognosis of HF.
Recently, a number of studies have reported an association
between the uric acid (UA) level and cardiovascular riskfactors or adverse cardiovascular outcomes [5-11]. Elevated
UA levels were also associated with HF. A high serum UA
level was an independent prognostic marker in patients
with moderate to severe chronic heart failure (CHF) [12].
However, the prognostic impact of serum UA levels in
patients with acute heart failure (AHF) is not well defined.
Moreover, the impact of combined UA and NT-ProBNP
levels as a prognostic marker in AHF is poorly understood.
The purpose of this study was to assess the prognostic
value of the combination of UA and NT-ProBNP levels as
an indicator of short-term outcomes in patients with AHF. 
METHODS
Study population
A total of 193 consecutive patients who were admitted to
the emergency department because of AHF were studied
retrospectively. AHF was defined as a rapid onset of signs
and symptoms secondary to abnormal cardiac function.
AHF could present as acute de novo (new onset HF in a
patient without previously known cardiac dysfunction) or
acute decompensation of CHF [13]. 
Laboratory measurements
Blood samples were obtained intravenously immediately
after admission. The serum UA level was measured by a
uricase-peroxidase method (ADVIA® 1650 Chemistry
System, Siemens Medical Solutions Diagnostics,
Tarrytown, NY, USA), and the plasma NT-proBNP level
was measured by immunoassay (Dimension® RxL Max®
Integrated Chemistry System, Siemens Healthcare
Diagnostics Inc, Deerfield, IL, USA). Other biochemical
parameters were measured according to standard techniques.
The rate of creatinine clearance (CrCl, mL/min) was
determined using the Cockcroft-Gault equation [14]. 
Study endpoint
The endpoint of this study was cardiovascular death
and/or readmission for heart failure within 3 months after
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Table 1. Patient characteristics at baseline according to event status 
Characteristics Patients with events Patients without events p value
(n = 28) (n = 165)
Age, yr 73.6 ± 11.5 68.4 ± 12.8 0.043
Male gender 9 (32.1) 67 (40.6) 0.395
Body mass index, kg/m2 21.8 ± 3.7 23.0 ± 3.7 0.145
Diabetes 7 (25.0) 52 (31.5) 0.489
Hypertension 9 (32.1) 78 (47.3) 0.137
Prior CHF 13 (46.4) 58 (35.2) 0.253
Coronary artery disease 18 (64.3) 79 (47.9) 0.108
NYHA class 0.111
III 18 (64.3) 129 (78.2)
IV 10 (35.7) 36 (21.8)
Atrial fibrillation 7 (25.0) 57 (34.5) 0.321
Echocardiographic parameter
LVEF, % 39.9 ± 18.1 42.5 ± 16.2 0.385
LVEDD, cm 5.46 ± 1.11 5.91 ± 4.55 0.628
LVESD, cm 4.35 ± 1.46 4.31 ± 1.23 0.877
LAD, cm 4.41 ± 0.71 4.59 ± 0.85 0.356
E / E’ ratio 21.94 ± 11.50 21.82 ± 12.74 0.967
Medication
ACE-I or ARB 8 (28.6) 89 (53.9) 0.013
Beta blockers 11 (39.3) 91 (55.2) 0.120
Diuretics 18 (64.3) 129 (78.2) 0.111
Values are presented as mean ± SD or number (%).
CHF, chronic heart failure; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-
diastolic diameter; LVESD, left ventricular end-systolic diameter; LAD, left atrial diameter; E / E’ ratio, ratio of peak early diastolic mitral
inflow to annular velocity; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.the initial admission.  
Statistical analysis
Continuous variables are expressed as mean ± standard
deviations. Independent groups were compared using the
unpaired Student’s t test. Categorical data were compared
with the chi-squared test, and Fisher’s exact test was
performed when relevant. The NT-ProBNP values were
log-transformed to reduce the effect of extreme values,
because the relationship between the NT-proBNP level
and the endpoint was not linear. Receiver operating
characteristic (ROC) curves were used to determine the
cut-off values for biochemical parameters. The optimal
values of UA and NT-ProBNP for predicting cardiac
events were defined as the concentrations with the largest
sensitivity plus specificity for the curves. Survival was
analyzed with Kaplan-Meier cumulative survival curves.
Differences in the survival rate were evaluated using the
log-rank test. Independent prognostic indicators for
clinical outcomes were evaluated by univariate and
multivariate Cox proportional hazard analysis. The results
are expressed as the hazard ratio (HR) and 95% confidence
interval (CI). Variables included in the multivariate
analysis were known risk factors and variables with p <
0.10 in the univariate analysis. The incremental prognostic
values of the UA and NT-ProBNP levels compared with
conventional risk factors were assessed by global chi-square
values calculated after adding in several independent
predictors identified by multivariate analysis, based on
increases in the overall likelihood ratio. The incremental
factors added to the model at each step were considered
significant when the difference in log-likelihood associated
with each model corresponded to p < 0.05. Statistical
analyses were performed using SPSS version 15.0 (SPSS
Inc., Chicago, IL, USA). Statistical significance was
defined at p< 0.05. 
RESULTS
Baseline characteristics
This study included 193 consecutive patients (age, 69 ±
13 years; 76 males) who presented to the emergency
department of a tertiary care hospital because of AHF.
During a 3-month follow-up, 23 patients (11.9%) died of
cardiovascular events and 20 patients (10.4%) were
readmitted for HF. The causes of cardiovascular deaths
were cardiogenic shock, pulmonary edema due to worsened
heart failure, and sudden death probably attributable to
ventricular arrhythmia. 
The baseline characteristics of the study subjects are
given in Table 1. Patients with cardiovascular events (n =
28) were older than those without events (n = 165), and
patients who had received angiotenin converting enzyme
(ACE) inhibitors or angiotensin receptor blockers (ARBs)
were less likely to have cardiovascular events. However,
the rates of diabetes and hypertension were similar
between the groups with and without cardiovascular
events, and there were no differences in echocardiographic
parameters between the two groups. 
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Table 2. Biochemical parameters at the time of clinical assessment for acute heart failure 
Parameter Patients with events Patients without events p value
(n = 28) (n = 165)
Uric Acid, mg/dL 9.18 ± 3.65 7.89 ± 2.87 0.083
Log NT-ProBNP 8.80 ± 1.35 8.11 ± 1.35 0.013
Creatinine, mg/dL 1.84 ± 1.51 1.28 ± 0.66 0.066
CrCl, mL/min 38.72 ± 26.49 56.11 ± 47.13 0.057
CRP, mg/dL 1.89 ± 3.31 1.95 ± 3.28 0.944
Hemoglobin, g/dL 12.11 ± 2.14 12.57 ± 2.20 0.310
Total cholesterol, mg/dL 170.6 ± 52.5 179.9 ± 47.5 0.341
Triglyceride, mg/dL 117.1 ± 65.3 114.3 ± 55.3 0.813
HDL-cholesterol, mg/dL 40.9 ± 13.5 45.4 ± 13.2 0.097
LDL-cholesterol, mg/dL 107.6 ± 43.9 117.6 ± 42.0 0.249
Values are presented as mean ± SD. 
NT-ProBNP, N-terminal prohormone brain natriuretic peptide; CrCl, creatinine clearance; CRP, C-reactive protein; HDL, high-density
lipoprotein; LDL, low-density lipoprotein.Biochemical parameters
Table 2 presents a comparison of biochemical parameters
between the groups with or without cardiovascular events.
Compared with patients without events, patients with
cardiovascular events showed significantly higher levels
of NT-ProBNP and UA, and a greater deterioration of
renal function parameters. However, no other biochemical
parameters differed significantly between the groups.
Predictors for cardiovascular events
The predictors of cardiovascular events based on
univariate and multivariate analyses are shown in Table 3.
The variables with significant predictive value in the
univariate Cox hazard analysis as well as conventional
risk factors were used for the multivariate analysis. The
univariate analysis revealed that patients with a high UA
level, a high NT-ProBNP level, and old age are at higher
risk for short-term cardiovascular events. Patients who
did not receive ACE inhibitors or ARBs also had a higher
risk of cardiovascular events. In the multivariate analysis,
a high UA level was the only significant independent
prognostic indicator for cardiovascular events (HR, 1.114;
95% CI, 1.009 to 1.230; p= 0.033).
Fig. 1 shows the ROC curves for the UA and NT-ProBNP
levels and the prediction of events. The area under the
ROC curve was similar between UA and NT-ProBNP
(0.623; 95% CI, 0.494 to 0.751, and 0.642; 95% CI, 0.528
to 0.757, respectively). For UA, the optimal level was
8.0 mg/dL, with a sensitivity of 67.9% and specificity
of 60.4%. For NT-ProBNP, the optimal level was 4210
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Table 3. Results of Cox hazard univariate and multivariate analyses for predictors of outcomes
Predictor Univariate HR (95% CI) p value Multivariate HR (95% CI) p value
Uric acid, mg/dL 1.103 (1.004 - 1.211) 0.041 1.114 (1.009 - 1.230) 0.033
Log NT-ProBNP 1.555 (1.109 - 2.181) 0.011 1.263 (0.897 - 1.780) 0.182
Age, yr 1.049 (1.007 - 1.094) 0.021 1.045 (0.997 - 1.096) 0.069
CrCl, mL/min 0.987 (0.971 - 1.004) 0.126 1.000 (0.985 - 1.015) 0.992
ACE-I or ARB  0.417 (0.181 - 0.959) 0.040 0.624 (0.258 - 1.511) 0.296
Diuretics  0.510 (0.232 - 1.121) 0.094 0.481 (0.201 - 1.151) 0.100
HR, hazard ratio; CI, confidence interval; NT-ProBNP, N-terminal prohormone brain natriuretic peptide; CrCl, creatinine clearance;
ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
Figure 1. Receiver-operating characteristic curves for uric acid
and N-terminal prohormone brain natriuretic peptide (NT-
proBNP) levels vs. cardiovascular events. AUC, area under the
curve.
Figure 2. Kaplan-Meier survival curves stratified by the
combination of uric acid (UA) and N-terminal prohormone
brain natriuretic peptide (NT-ProBNP). pg/mL, with a sensitivity of 71.4% and specificity of
50.3%. 
The Kaplan-Meier survival curve for combined cardio-
vascular events showed that patients with a UA level > 8.0
mg/dL and NT-ProBNP level > 4,210 pg/mL were at
higher risk for cardiovascular events, compared with
patients with UA ≤ 8.0 mg/dL and NT-ProBNP ≤ 4,210
pg/mL (HR, 5.840; 95% CI, 1.677 to 20.333; p = 0.006)
(Fig. 2). The global chi-square analysis showed an
incremental, although not statistically significant,
improvement of 4 in the prognostic value with the
addition of the NT-ProBNP level and of 8 with the
addition of the UA level, compared with the prognostic
value of conventional risk factors such as age and
creatinine clearance. The addition of the combined NT-
ProBNP and UA levels gave a greater incremental increase
in the prognostic value (Fig. 3). 
DISCUSSION
This study demonstrated that UA was an important
prognostic factor for short-term clinical outcome in
patients with AHF. Moreover, the combination of the UA
and NT-ProBNP levels had additional value for predicting
the prognosis in patients with AHF. 
UA is the final product of purine metabolism [15], and
hypoxic states cause an elevation of the serum UA level
[16]. The activation of the xanthine oxidase (XO) system
by tissue hypoxia increases UA production and causes
hyperuricemia. Thus, hyperuricemia is a marker for
impaired oxidative metabolism, and UA levels reflect the
degree of XO activation [16]. Cell death, tissue hypoxia,
and impaired metabolism in HF increase XO activity,
leading to an overproduction of UA. Increased UA in the
circulation of HF patients may result from an increased
generation of UA, a decreased excretion of UA ,or a
combination of both; however, overproduction of UA
appears to be the dominate factor accounting for elevated
UA levels in CHF [17]. 
Numerous studies have demonstrated the prognostic
importance of hyperuricemia in patients with CHF. Anker
et al. [12] have reported that a high serum UA level is a
strong, independent marker of poor prognosis in patients
with moderate to severe CHF. Sakai et al. [18] have shown
that UA is released from the heart in CHF patients,
that the UA transcardiac gradient correlates with left
ventricular ejection fraction, and that a high serum UA
level is an important predictor of mortality, independent
of factors such as glomerular filtration rate and BNP level,
which are known predictors of poor prognosis in patients
with mild to severe CHF. Other studies have suggested
that the inhibition of XO may improve myocardial
function [19] and ejection fraction [20] in patients with
HF. Moreover, Struthers et al. [21] have demonstrated
that long-term, high-dose allopurinol treatment, rather
than long-term, low-dose allopurinol treatment, may be
associated with decreased mortality in patients with CHF.
Recently, some studies have suggested that the UA level
may be a prognostic marker in the setting of AHF. Pascual-
Figal et al. [22] have reported the long-term clinical
prognostic value of hyperuricemia in patients with AHF,
showing that the UA level prior to discharge was associated
with higher risk for death, heart failure readmission, and a
combination of both events. The present study also
suggested that serum UA has prognostic value in patients
with AHF. 
In several previous reports, the overproduction of UA
by XO activation was the predominant underlying
mechanism of hyperuricemia in CHF patients [19,23]. The
pathophysiological role and mechanism of hyperuricemia
may differ between AHF and CHF. However, there is no
established mechanism to explain the cause of hype-
ruricemia in patients with AHF. In our opinion, cell death
or apoptosis caused by ischemic insult or acute deterioration
of renal function may be the dominant factor for hype-
ruricemia in AHF. More studies are warranted to determine
the pathophysiological mechanism of hyperuricemia in
patients with AHF. 
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Figure 3. Incremental prognostic value of the N-terminal
prohormone brain natriuretic peptide (NT-ProBNP) level, uric
acid (UA) level, and combined NT-ProBNP and UA levels
compared with conventional risk factors.Traditionally, BNP has been an important prognostic
predictor in patients with HF [24,25]. The hypothesis of
the present study was that the combination of the UA and
NT-ProBNP levels also has a prognostic role in patients
with AHF. In the present study, patients with a high UA or
high NT-ProBNP level showed a poorer prognosis than
patients with lower levels. Additionally, the combination
of the UA and NT-ProBNP levels provided incremental
prognostic value to that of conventional risk factors.
Therefore, the combination of UA and NT-ProBNP levels
appears to be a more powerful prognostic indicator for
short-term clinical outcome in the setting of AHF, and risk
stratification of patients according to the UA and NT-
ProBNP levels is possible. 
In this study, serum UA and NT-ProBNP levels obtained
on admission were used for analysis. Biochemical markers
obtained prior to discharge would have had limitations
in predicting short-term clinical outcome, because they
would not reflect the impact on clinical events such as in-
hospital deaths. The purpose of this study was to assess
the prognostic value of UA and NT-ProBNP levels in
predicting short-term outcome; thus laboratory data
obtained on admission were used for the analysis.
UA is excreted primarily by the kidney; therefore, a
close relationship among the UA level, renal function, and
diuretic treatment would be expected. However, previous
studies have demonstrated that the prognostic value of
UA is independent of these variables [22]. Multivariate
analysis in the present study also showed that the
prognostic value of UA is independent of renal function
and diuretic treatment. The NT-ProBNP concentration is
similarly affected by renal function. Nevertheless, the use
of NT-ProBNP testing is valuable for the evaluation of
patients with HF, irrespective of renal function [26]. 
In conclusion, although the UA level is an independent
prognostic predictor for short-term clinical outcome in
patients with AHF, the combination of UA and NT-ProBNP
levels appears to be a more useful prognostic marker for
short-term outcome in the setting of AHF.  
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